GLP-1 Medications and Pregnancy Planning: When to Stop and What to Know
If you are on semaglutide or tirzepatide and planning to become pregnant, here is what you need to know about washout periods, fertility benefits, and safe transitions.
Important Medical Warning: GLP-1 medications (semaglutide, tirzepatide, retatrutide) are contraindicated during pregnancy. Animal studies have shown potential fetal harm. Always work with your healthcare provider on pregnancy planning while on these medications.
GLP-1 medications like semaglutide and tirzepatide have transformed weight management for millions of patients. But if pregnancy is on your horizon, planning the transition off these medications is critical for both your health and your future baby's safety.
Why You Must Stop GLP-1s Before Pregnancy
All GLP-1 receptor agonists carry pregnancy category warnings based on animal reproduction studies showing adverse fetal outcomes. While human data is limited, the current medical consensus is clear: these medications should be discontinued before conception.
- Animal studies showed increased pregnancy loss and fetal abnormalities
- GLP-1 medications reduce nutrient absorption, which could affect fetal development
- Significant caloric restriction during pregnancy is harmful regardless of the cause
- There is no established safe dose during pregnancy
Washout Periods by Medication
| Medication | Half-Life | Recommended Washout |
|---|---|---|
| Semaglutide | ~7 days | 2 months (8 weeks) |
| Tirzepatide | ~5 days | 1 month (4 weeks) |
| Retatrutide | ~6 days | 2 months (consult provider) |
These recommendations allow approximately 5 half-lives to pass, ensuring the medication is essentially cleared from your system. Your provider may recommend longer washout periods based on your dose and individual factors.
The Fertility Upside
Here is the encouraging news: losing weight with GLP-1 medications before conception can significantly improve fertility outcomes. Obesity is a major contributor to:
- Anovulation: Excess weight disrupts ovulation. Losing 5-10% of body weight can restore regular ovulation in many patients
- PCOS: Weight loss improves hormonal balance in polycystic ovary syndrome, the most common cause of infertility
- IVF success: Lower BMI is associated with better IVF outcomes and fewer complications
- Pregnancy complications: Pre-pregnancy weight loss reduces risks of gestational diabetes, preeclampsia, and cesarean delivery
Many reproductive endocrinologists now support GLP-1 use as a pre-conception weight optimization strategy, provided the medication is stopped with adequate washout time.
Creating Your Transition Plan
Step-by-Step Transition Guide
- Reach your target weight first: Work with your provider to reach a healthy BMI before planning the washout
- Establish maintenance habits: Build exercise and nutrition habits that will sustain you without medication
- Taper if recommended: Some providers recommend dose reduction before stopping rather than abrupt discontinuation
- Begin washout period: Stop medication according to the recommended timeline above
- Start prenatal vitamins: Begin folate supplementation at least 1 month before conception, ideally 3 months
- Monitor weight: Track weight during washout and work with your provider if significant regain occurs
- Begin conception attempts: After the washout period is complete
Managing Weight During Washout
The biggest concern most patients have is weight regain after stopping GLP-1 medications. Studies show that approximately two-thirds of weight lost is regained within a year of stopping. During the washout period:
- Focus on protein intake (1g per pound of ideal body weight) to preserve muscle
- Maintain the portion sizes you established while on medication
- Continue regular exercise, especially strength training
- Some mild weight regain (3-5 lbs) is normal as appetite increases
- Work with a dietitian who understands GLP-1 transitions
Contraception Considerations
An important safety note: GLP-1 medications can reduce the effectiveness of oral contraceptives by slowing gastric emptying and potentially reducing absorption. If you are on GLP-1 medication and not yet ready to conceive, consider barrier methods or non-oral hormonal contraception (patch, ring, IUD) for reliable protection.
Frequently Asked Questions
How long before trying to conceive should I stop GLP-1 medication?
Most providers recommend stopping semaglutide at least 2 months before attempting conception, and tirzepatide at least 1 month before. These washout periods are based on the medications' half-lives. Always follow your specific provider's guidance.
Can GLP-1 medications affect fertility?
Weight loss from GLP-1 medications can actually improve fertility in patients with obesity-related infertility or PCOS. However, the medications themselves should not be taken during active conception attempts or pregnancy due to insufficient safety data.
Will I regain weight after stopping GLP-1s before pregnancy?
Some weight regain is common after stopping GLP-1 medications. A structured maintenance plan with your provider, including nutrition guidance and exercise, can minimize regain during the washout period and pregnancy.
Is it safe to take GLP-1 medications while breastfeeding?
GLP-1 medications are not recommended during breastfeeding due to limited safety data. Discuss postpartum weight management options with your provider. Some patients resume GLP-1 therapy after weaning.
Plan Your Pre-Pregnancy Journey with Trimi
Our clinicians help you optimize your weight before pregnancy with compounded semaglutide ($99/mo) or tirzepatide ($125/mo), including transition planning for when you are ready to conceive.
Get Started TodayMore on Life Events
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication or treatment program.
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).